Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 24;10:559896. doi: 10.3389/fonc.2020.559896

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Xiang, Fu, Wang, Li, Zheng, Nan and Tian.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Tumor mutation burden and copy number alteration burden correlated with clinical response to immune checkpoint inhibitor treatment. (A,B) Progression-free survival curve for patients receiving ICI (PD-1/L1 inhibitor or in combination with anti-CTLA-4) based on tumor mutation burden (A) or copy number alteration burden (B). (C,D) Progression-free survival curve for KRAS-mutant patients receiving ICI (PD-1/L1 inhibitor or in combination with anti-CTLA-4) based on tumor mutation burden (C) and copy number alteration burden (D). (E,F) Proportional representation of durable clinical benefits in advanced lung adenocarcinoma patients receiving ICI (PD-1/L1 inhibitor or in combination with anti-CTLA-4). (G,H) Proportional representation of durable clinical benefits in advanced KRAS-mutant lung adenocarcinoma patients receiving ICI (PD-1/L1 inhibitor or in combination with anti-CTLA-4). (I,J) Progression-free survival curve for patients receiving PD-1/PD-L1 inhibitor alone based on tumor mutation burden (I) and copy number alteration burden (J). (K,L) Proportional representation of durable clinical benefits in advanced KRAS-mutant lung adenocarcinoma patients receiving PD-1/PD-L1 inhibitor alone. MUT, mutant; WT, wild-type; DCB, durable clinical benefit; NDB, no durable clinical benefit.